Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT

E. Snarski, J. Stringer, M. Mikulska, L. Gil, G. Tridello, P. Bosman, A. Lippinkhof, J. Hoek, M. Karas, S. Zver, C. Lueck, N. Blijlevens, I. González, M. Ociepa-Wasilkowska, M. Górka, I. Sánchez-Ortega, I. Andersson, L. Yáñez, MA. Bekadja, J. Styczynski

. 2021 ; 56 (12) : 2929-2933. [pub] 20210821

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22011778
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Freely Accessible Science Journals od 1997 do Před 1 rokem
ProQuest Central od 1997-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem

Odkazy

PubMed 34420041
DOI 10.1038/s41409-021-01430-7
Knihovny.cz E-zdroje

The current guidelines for prevention of infections in hematopoietic stem cell transplantation (HSCT) do not specify which central venous catheter (CVC) insertion site should be preferred in allogeneic HSCT recipients-internal jugular vein (IJV) or subclavian vein (SCV). We designed a multicenter prospective observational study comparing the risk of infectious and non-infectious complications between the two most common sites of CVC insertion (IJV and SCV) in allogeneic HSCT. There were in total 232 consecutive patients (86 IJV and 146 SCV) who underwent adult allogeneic HSCT reported from 11 centers in 8 countries. The center independent analysis of central line associated/related blood stream infections with ECDC criteria has shown statistically significant difference favoring SCV (23% IJV vs 13% SCV (OR 2.03 (1.01-4.06), p = 0.047)). The differences in CLABSI per 1000 days of CVC use favored SCV over IJV (7.93/1000 days IJV vs 2.79/1000 days SCV, p = 0.002). The frequency of all non-infectious complications was similar in both arms-13% IJV and 12% SCV (OR 1.1 (0.5-2.5), p = 0.8). This multicenter prospective study showed statistically significant lower confirmed number of CLABSI per 1000 days of CVC use without higher risk of noninfectious complications related to the subclavian insertion site in allogeneic HSCT recipients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011778
003      
CZ-PrNML
005      
20220506125824.0
007      
ta
008      
220425s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-021-01430-7 $2 doi
035    __
$a (PubMed)34420041
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Snarski, Emilian $u Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Warsaw, Poland. emiliansnarski@gmail.com $1 https://orcid.org/0000000327007571
245    10
$a Risk of infectious complications in adult patients after allogeneic hematopoietic stem cell transplantation depending on the site of central venous catheter insertion-multicenter prospective observational study, from the IDWP EBMT and Nurses Group of EBMT / $c E. Snarski, J. Stringer, M. Mikulska, L. Gil, G. Tridello, P. Bosman, A. Lippinkhof, J. Hoek, M. Karas, S. Zver, C. Lueck, N. Blijlevens, I. González, M. Ociepa-Wasilkowska, M. Górka, I. Sánchez-Ortega, I. Andersson, L. Yáñez, MA. Bekadja, J. Styczynski
520    9_
$a The current guidelines for prevention of infections in hematopoietic stem cell transplantation (HSCT) do not specify which central venous catheter (CVC) insertion site should be preferred in allogeneic HSCT recipients-internal jugular vein (IJV) or subclavian vein (SCV). We designed a multicenter prospective observational study comparing the risk of infectious and non-infectious complications between the two most common sites of CVC insertion (IJV and SCV) in allogeneic HSCT. There were in total 232 consecutive patients (86 IJV and 146 SCV) who underwent adult allogeneic HSCT reported from 11 centers in 8 countries. The center independent analysis of central line associated/related blood stream infections with ECDC criteria has shown statistically significant difference favoring SCV (23% IJV vs 13% SCV (OR 2.03 (1.01-4.06), p = 0.047)). The differences in CLABSI per 1000 days of CVC use favored SCV over IJV (7.93/1000 days IJV vs 2.79/1000 days SCV, p = 0.002). The frequency of all non-infectious complications was similar in both arms-13% IJV and 12% SCV (OR 1.1 (0.5-2.5), p = 0.8). This multicenter prospective study showed statistically significant lower confirmed number of CLABSI per 1000 days of CVC use without higher risk of noninfectious complications related to the subclavian insertion site in allogeneic HSCT recipients.
650    12
$a katetrizace centrálních vén $x škodlivé účinky $7 D002405
650    12
$a centrální žilní katétry $x škodlivé účinky $7 D062905
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    _2
$a vena subclavia $7 D013350
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Stringer, Jacqui $u NHS Christie Tr, Manchester, UK
700    1_
$a Mikulska, Małgorzata $u Division of Infectious Diseases, Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy $u Division of Infectious Diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy $1 https://orcid.org/0000000255354602
700    1_
$a Gil, Lidia $u Department of Hematology and Bone Marrow Transplantation, Poznan University of Medical Sciences, Poznan, Poland
700    1_
$a Tridello, Gloria $u Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
700    1_
$a Bosman, Paul $u EBMT Data Office Leiden, Leiden, The Netherlands $1 https://orcid.org/0000000214739442
700    1_
$a Lippinkhof, Anne $u EBMT Data Office Leiden, Leiden, The Netherlands
700    1_
$a Hoek, Jennifer $u EBMT Data Office Leiden, Leiden, The Netherlands
700    1_
$a Karas, Michal $u Charles University Hospital, Pilsen, Czech Republic
700    1_
$a Zver, Samo $u University Medical Centre, Ljubljana, Slovenia
700    1_
$a Lueck, Catherina $u Hannover Medical School, Hannover, Germany
700    1_
$a Blijlevens, Nicole $u Radboud University Medical Centre, Nijmegen, The Netherlands
700    1_
$a González, Iria $u Hospital Santa Creu i Sant Pau, Barcelona, Spain
700    1_
$a Ociepa-Wasilkowska, Małgorzata $u Maria Sklodowska-Curie Institute, Gliwice, Poland
700    1_
$a Górka, Michał $u Department of Hematology, Transplantology and Internal Medicine, Central University Hospital, Medical University of Warsaw, Warsaw, Poland
700    1_
$a Sánchez-Ortega, Isabel $u ICO-Hospital Duran i Reynals, Barcelona, Spain
700    1_
$a Andersson, Inger $u Sahlgrenska University Hospital, Gothenburg, Sweden
700    1_
$a Yáñez, Lucrecia $u Hospital University Marqués de Valdecilla, Santander, Spain
700    1_
$a Bekadja, Mohamed-Amine $u University Hospital Establishment 1st November, Oran, Algeria
700    1_
$a Styczynski, Jan $u Collegium Medicum UMK Torun, University Hospital, Bydgoszcz, Poland. jstyczynski@cm.umk.pl $1 https://orcid.org/000000023158119X
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 56, č. 12 (2021), s. 2929-2933
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34420041 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506125816 $b ABA008
999    __
$a ok $b bmc $g 1789397 $s 1162976
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 56 $c 12 $d 2929-2933 $e 20210821 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace